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http://dxObjectives: To describe the incidence and severity of right ventricular dysfunction (RVD) in pediatric ventric-
ular assist device (VAD) recipients and to identify the preoperative characteristics associated with RVD and their
effect on outcomes.
Methods:Children bridged to transplantation from 2004 to 2011 were included. RVDwas defined as the use of a
left VAD (LVAD) with an elevated central venous pressure of>16 mm Hg with inotropic therapy and/or inhaled
nitric oxide for>96 hours or biventricular assist (BiVAD).
Results: A total of 57 children (median age, 2.97 years; range 35 days to 15.8 years) were supported. Of the 57,
43 (75%) had an LVAD, and of those, 10 developed RVD. The remaining 14 (25%) required BiVAD. Thus, RVD
occurred in 24 of 57 patients (42%). Preoperative variables such as younger age (P¼ .01), use of extracorporeal
mechanical support (P¼ .006), and elevated urea (P¼ .03), creatinine (P¼ .02), and bilirubin (P¼ .001) were
associated with RVD. Multiple logistic regression analysis indicated that elevated urea and extracorporeal me-
chanical support (odds ratio, 26.4; 95% confidence interval, 2.3-307.3; and odds ratio, 27.8; 95% confidence
interval, 2.5-312.3, respectively) were risk factors for BiVAD. The patients who developed RVD on LVAD
had a complicated postoperative course but excellent survival (100%), comparable to those with preserved right
ventricular function (91%). The survival for those requiring BiVAD was reduced (71%).
Conclusions: RVD occurred in approximately 40% of pediatric VAD recipients and affects their
peri-implantation morbidity and bridging outcomes. Preoperative extracorporeal membrane oxygenation and
elevated urea were risk factors for BiVAD. Additional studies of the management of RVD in children after
VAD implantation are warranted. (J Thorac Cardiovasc Surg 2014;147:1691-7)Supplemental material is available online.
Mechanical bridging with ventricular assist devices (VADs)
has recently become an effective treatment option for
children awaiting heart transplantation. The Berlin Heart
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P
MAn important question that has not been addressed in
children is the right ventricular (RV) response to implanta-
tion of a left ventricular assist device (LVAD) and how to
distinguish those patients who will require biventricular
assist device (BiVAD).
In adults, considerable research has been done on RV
dysfunction (RVD) after LVAD implantation showing that
RVD is 1 of the key determinants of the bridging outcome.
Preoperative risk factors have been identified and used to
assess the likelihood of RV compromise in adult VAD
recipients.4-8
However, some of the identified risk factors for RVD in
adults might not exist or be applicable to children.
Moreover, several reports of VAD use in children have
highlighted a reduction in the use of BiVAD over time;
however, the criteria for mechanical RV support in children
have varied among centers.1,3,9
The present study aimed to describe the incidence and
severity of RVD in children bridged with the Berlin
Heart EXCOR VAD; to identify the preoperative charac-
teristics associated with RVD requiring a BiVAD; and to
assess the effect RVD has on postoperative morbidity and
outcomes.diovascular Surgery c Volume 147, Number 5 1691
Abbreviations and Acronyms
BiVAD ¼ biventricular assist device
DCM ¼ dilated cardiomyopathy
ECMO ¼ extracorporeal membrane oxygenation
LVAD ¼ left ventricular assist device
OR ¼ odds ratio
RRT ¼ renal replacement therapy
RV ¼ right ventricular
RVAD ¼ right ventricular assist device
RVD ¼ right ventricular dysfunction
VAD ¼ ventricular assist device
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MMETHODS
The present study was a retrospective, observational cohort study
using the data from patients treated in 2 tertiary-care pediatric trans-
plant centers from November 2004 to January 2011. All patients aged
<16 years who were bridged to transplantation with the Berlin Heart
EXCOR Pediatric VAD were identified at these centers from the data-
bases. The databases included prospective information on the patient
demographic data, VAD implantation details, and outcomes. Additional
data for the study were gathered retrospectively (see the section ‘‘Data
Collection’’). The respective institutional research ethics review boards
of the 2 centers approved the study, and a waiver of informed consent
was obtained.
VAD Management
All children were supported using a Berlin Heart EXCOR Pediatric
VAD. The 2 study sites had a uniform approach to VAD implantation,
with the expectation of LVAD only support in most cases. The pump size
was chosen according to the Berlin Heart Company protocol, and the
VAD rate was set to achieve a cardiac index of 2.4 to 2.8 L/min/m2.9
Left ventricular unloading, cannula placement, and RV function were
assessed using intraoperative transesophageal echocardiography. When
weaning off cardiopulmonary bypass, the circulating blood volume was
optimized and the right ventricle was supported with inotropes, inhaled
nitric oxide, and pacing, if necessary. The addition of a right VAD
(RVAD) was reserved for patients who could not separate from cardiopul-
monary bypass despite optimal medical right heart support. The strategy
for treating children with a VAD, including anticoagulation, has been
previously published.10
Data Collection
Preoperative and operative data. The preimplantation data
included the patient demographic data, diagnosis, mechanical ventilation
and intravenous inotropic support duration, extracorporeal membrane
oxygenation (ECMO) period, highest central venous pressure within 24
hours before VAD implantation, and laboratory test results (hepatic and
renal function, blood count, and coagulation status). The preimplantation
transthoracic echocardiograms were also reviewed by a cardiologist who
was unaware of the treatment group with attention to the following: right
atrial and left atrial area, tricuspid regurgitation grade (0, none; 1, mild;
2, moderate; and 3, severe), tricuspid regurgitation velocity (an estimate
of RV systolic pressure), tricuspid valve annulus size, RV end-diastolic
dimension, and qualitative RV function (0, normal; 1, mild dysfunction;
2, moderate dysfunction; and 3, severe dysfunction). The operative data
included the duration of cardiopulmonary bypass and transfusion of red
blood cells and other blood products within the first 24 hours after
implantation.1692 The Journal of Thoracic and Cardiovascular SurOutcomes
RV dysfunction. RVD was defined as LVAD with an elevated central
venous pressure>16 mm Hg with inotropes (other than milrinone) and/or
inhaled nitric oxide therapy>96 hours, or a need for BiVAD. Other condi-
tions with similar clinical signs were excluded (eg, tamponade,
pneumothorax, effusions, or ventricular arrhythmia).
According to the increasing severity of RVD, the patients were divided
into the following categories: LVAD with no RVD (LVAD-only group),
LVAD with medically managed RVD (LVAD-RVD group); and LVAD
with RVD requiring an RVAD (BiVAD group).
Morbidity and mortality. Postoperative complications, such as
bleeding, a requirement for mediastinal exploration or placement of a
chest drain, and renal failure requiring renal replacement therapy
(RRT) with peritoneal dialysis or hemofiltration, were recorded. The
duration of postoperative mechanical ventilation after VAD implantation
was recorded. In-hospital mortality was also recorded.
Statistical Analysis
Preoperative and operative variables and RVD. Conti-
nuous data are presented as the mean  standard deviation for normally
distributed data or the median and range otherwise. The categorical and
ordinal data are presented as numbers and percentages. Comparisons
between groups using continuous data were performed using analysis of
variance for normally distributed data and the Kruskal-Wallis test
otherwise. For comparisons using categorical or ordinal data, the c2 or
Fisher exact test was performed. Assuming the 3 groups (LVAD-only,
LVAD-RVD, and BiVAD) represented an ordered group (increasing levels
of RVD), a nonparametric (Wilcoxon-type) test for trend was performed to
assess the trends in continuous variables across the 3 ordered groups.
Risk factors for BiVAD. For the assessment of the risk factors for
BiVAD, all patients treated with LVAD only were used as the reference
group. Comparisons using continuous variables were performed using
the Student’s t test for normally distributed data or the Wilcoxon rank
sum test otherwise. Comparisons using ordinal or categorical data were
performed using the c2 or Fisher exact test. Variables identified as
significantly associated with the need for BiVAD support were entered
into a multiple logistic regression model to identify the independent risk
factors for BiVAD implantation and calculation of the odds ratios (ORs)
and their respective 95% confidence intervals.
Outcomes after RVD. Comparisons of the outcomes were per-
formed for all 3 groups. Additionally, we sought to determine whether
any differencewas present in the outcomes in the LVAD-RVD group versus
the LVAD group without RVD. Differences in the duration of postoperative
ventilation and hospital length of stay were analyzed using a Kruskal-
Wallis test orWilcoxon rank sum test. Differences in the complication rates
and in-hospital mortality were assessed using the c2 test or Fisher exact
test.
Statistical analysis was performed using Stata, version 9.2 (StataCorp
LP, College Station, Tex).
RESULTS
Baseline Demographics
A total of 57 children (28 males and 29 females) at a
median age of 2.97 years (range, 35 days to 15.8 years)
and median weight of 12.8 kg (range, 3.6-90) underwent
VAD implantation during the study period. In all patients,
the indication for VAD support was end-stage heart failure
with the intention to bridge the patient to cardiac transplan-
tation. Five patients with congenital heart disease (all with
single ventricle physiology) who were bridged during
the study period were excluded from the present study.gery c May 2014
FIGURE 1. Proportions and survival rates of patients with a left ventri-
cular assist device (LVAD) with and without right ventricular dysfunction
(RVD) and those with a biventricular assist device (BiVAD). VAD,
Ventricular assist device; OHT, orthotopic heart transplant; Wean,
ventricular assist device weaned and explanted.
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MPatients with congenital heart disease and biventricular
circulation had not undergone VAD implantation during
the study period. Of the 57 included children, 43 (75%)
were supported with LVAD and 14 (25%) with BiVAD.
Most of the children, 42 (74%), had a diagnosis of dilated
cardiomyopathy (DCM). The remaining 15 children
(26%) were grouped together as a non-DCM group and
had a diagnosis of confirmed viral myocarditis in 5, left ven-
tricular noncompaction in 3, restrictive cardiomyopathy in
2, myocardial dysfunction secondary to complications of
Kawasaki disease in 2, rheumatic heart disease in 2, and hy-
pertrophic cardiomyopathy in 1.
RVD Incidence
Of the 43 patients supported with an LVAD, 33 (77%)
had preserved right heart function (LVAD-only), and 10
(23%) had developed RVD (LVAD-RVD). Inhaled nitric
oxide was used in 6 of the 10 LVAD-RVD patients
(60%). Of the 14 patients requiring BiVAD, the RVAD
was implanted at LVAD implantation in all but 1 patient,
who required RVAD implantation on day 22 of support
for persistent RVD complicated by sepsis (Figure 1).
RVD and Demographic and Perioperative Data
The associations between the severity of RVD and the
demographic and preoperative data are listed in Table 1.
Differences in the underlying cardiac diagnosis were of
borderline statistical significance among the groups,
with the DCM diagnosis occurring more frequently in the
LVAD-only group. Increased RVD severity was also
associated with increasing patient weight and age and
derangement of preoperative renal and hepatic function.
ECMO had frequently been used before VAD implantation
(24 of 57 [42.1%]), and the patients in the BiVAD group
had received this therapy most frequently.
The only variable identified from the preoperative
echocardiographic findings that was associated with
postoperative RVD was a qualitative impairment in RV
function (LVAD-only, median, 0 [range, 0-2]; vs LVAD-
RVD, median, 0.5 [range, 0-3]; vs BiVAD, median 2
[range, 0-3]; P ¼ .01). None of the other preoperative
echocardiographic variables were significantly different
across the 3 groups of patients (Table E1).
The intraoperative variables for the 3 groups are listed in
Table 2. In the patients successfully treated with an LVAD,
neither the cardiopulmonary bypass duration (P ¼ .7) nor
the transfusion volumes (P ¼ .17) were different between
the patients with and without RVD.
Risk Factors for BiVAD
BiVADwas used in 14 of the 57 patients (24.6%), and the
rate of BiVAD use did not differ by year of implantation
(P ¼ .59). Compared with the LVAD patients, the BiVAD
patients were significantly older (median age, 7.5 years;The Journal of Thoracic and Carrange, 3.7 months to 15.8 years; vs 1.8 years, range, 1.2
months to 15.7 years; P ¼ .02). Only 1 of the 16 patients
aged < 1 year required a BiVAD. The BiVAD patients
were also more likely to have received ECMO before
VAD implantation (11 of 14 [79%] vs 13 of 43 [30%];
P ¼ .02). Compared with the patients with DCM, a trend
was seen for the non-DCM group to require BiVAD more
frequently (8 of 42 [19%] vs 6 of 15 [40%], P ¼ .1).
The preoperative laboratory study results demonstrated
significantly greater levels of urea (median, 10.2 mmol/L;
range, 3.6-36.1; vs 6, range, 1.5-29.0 mmol/L, P ¼ .03),
alanine aminotransferase (median, 84.5 mkat/L, range,
23-1780; vs 39 mkat/L; range, 6-1610; P ¼ .034), and
bilirubin (median, 31.5 mmol/L; range, 6-246; vs 11.5,
range, 2-109; P ¼ .02) in patients requiring BiVAD
compared with those requiring LVAD.
Multiple logistic regression analysis was performed to
identify the independent risk factors for BiVAD implanta-
tion, including age, pre-implantation urea, and use of
ECMO in the model. Serum urea was entered as a
dichotomous variable, defined by an abnormal value of
>10 mmol/L. Hepatic function tests were not included in
the analysis because test results were not available for
25% of the patients. Only the urea level and ECMO
use before implantation were statistically significant
(OR, 26.4; 95% CI, 2.3-307.3; and OR, 27.8, 95% CI,
2.5-312.3, respectively). A trend in significance was found
for infants (aged<1 year) to require BiVAD less frequently
(OR, 0.09; 95% CI, 0.01-1.2).Postoperative Morbidity and Survival
The postimplantation morbidity of the 3 groups is listed
in Table 3. RRT was required in up to one third of the
BiVAD and LVAD-RVD patients, whereas the need for
RRT in the LVAD-only group was infrequent (4 of 12
[33%] vs 4 of 10 [40%] vs 2 of 33 [6%]; P ¼ .02). In all
surviving patients, renal function recovered sufficiently
for the patients to be weaned off RRT before heart
transplantation.diovascular Surgery c Volume 147, Number 5 1693
TABLE 1. Demographic and pre-VAD implantation characteristics
Characteristic LVAD only (n ¼ 33) LVAD-RVD (n ¼ 10) BiVAD (n ¼ 14) P value
DCM 28 (85) 6 (60) 8 (57) .08
Female gender 18 (55) 6 (60) 5 (36) .45
Weight (kg) 11 (3.8-68) 17.5 (3.6-80) 19 (6.2-90) .04
Age (y) 1.7 (36 d to 15.7 y) 3.9 (35 d to 15.4 y) 8.9 (110 d to 15.8 y) .012
CVP (mm Hg) 10 (5-25) 14.5 (5-19) 16.5 (13-21) .004
Inotropes (d) 10 (1-52) 14 (5-132) 6 (0-51) .44
Inotropes
Milrinone 30 (91) 10 (100) 10 (71) .11
Adrenaline 17 (51.5) 5 (50) 9 (64.3) .69
Noradrenaline 2 (6.1) 1 (10) 4 (28.6) .09
Dopamine 6 (18.2) 2 (20) 1 (7.2) .68
Dobutamine 14 (42.4) 4 (40) 4 (28.6) .7
Antiarrhythmics 4 (16.1) 1 (10) 4 (28.6) .15
Mechanical ventilation 25 (75.8) 5 (50) 12 (85.7) .15
Ventilation (d) 9.5 (0-44) 2 (0-45) 7 (0-49) .53
RRT 1 (3) 0 (0) 3 (21.8) .07
ECMO 10 (30) 3 (30) 11 (79) .006
ECMO duration (d) 0 (0-38) 0 (0-40) 5.5 (0-30) .077
Urea (mmo/L) 6 (1.5-20.3) 7.6 (3.5-29) 10.2 (3.6-36.1) .026
Creatinine (mmol/L) 35 (4.2-89) 73 (25-86) 55.5 (19-192) .026
PT (s) 13.5 (10.3-163) 15.2 (10-100) 21.4 (10.8-96) .13
Bilirubin (mmol/L)* 10 (2-100) 26 (11-109) 31.5 (6-246) .001
ALT (mkat/L)y 29 (6-1610) 93 (17-1260) 84.5 (23-1780) .005
Sodium (mmol/L) 138 (123-163) 135.5 (120-148) 143.5 (132-156) .2
Data presented as n (%) or median (range). VAD, Ventricular assist device; LVAD, left VAD; RVD, right ventricular dysfunction; BiVAD, biventricular assist device;DCM, dilated
cardiomyopathy; CVP, central venous pressure; RRT, renal replacement therapy; ECMO, extracorporeal membrane oxygenation; PT, prothrombin time; ALT, alanine
aminotransferase. *Available for 44 of 57 patients. yAvailable for 43 of 57 patients.
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P
MThe overall survival to hospital dischargewas 88% (50 of
57). Of the survivors, 49 patients survived to transplantation
and 1 underwent VAD explantation and was discharged
home. The survival was similar in the children with
and without RVD treated with LVAD support (Figure 1);
however, it was lower in the BiVAD group (OR, 0.19;
95% CI, 0.03-0.98). The details of the nonsurvivors are
listed in Table 4. Of the 7 patients who died, 2 died
intraoperatively (both patients were treated during the first
year of the VAD program and they both died of multiorgan
failure after late conversion from ECMO).DISCUSSION
The results of the present study have demonstrated that
there is a spectrum of response in RV performance to
VAD implantation in children. Most children can be
bridged to transplantation with an LVAD only, althoughTABLE 2. Intraoperative characteristics
Characteristic LVAD only (n ¼ 33) L
CPB (min) 104 (72-173)
RBC (mL/kg) 46.8 (9.7-169.0)
Total blood products (mL/kg) 72.9 (16.0-241.0)
Total blood products (mL) 877.5 (250-2100)
Data presented as median (range). LVAD, Left ventricular assist device; RVD, right ventric
RBC, red blood cell.
1694 The Journal of Thoracic and Cardiovascular Surapproximately 1 in 4 LVAD recipients developed RVD
and needed aggressive pharmacologic RV support and a
longer postoperative course in intensive care. Their overall
survival, however, was excellent. Severe RVD requiring
BiVAD support occurred in 25% of the VAD recipients,
consistent with the rate of previous studies, and those
patients had significantly reduced survival.1,3,9
These findings suggest that a period of medical manage-
ment for patients with RVD that develops after LVAD
implantation (which can persist for several days) is
warranted in most cases.Right Ventricle and VAD
Deterioration of RV function is an acute event observed
in a significant proportion of patients after LVAD implanta-
tion. It has been studied in adults and recognized as one of
the determinants of morbidity and mortality.4,11-13 SeveralVAD-RVD (n ¼ 10) BiVAD (n ¼ 14) P value
121 (80-170) 196 (87-465) .01
18.3 (6.5-109.1) 37.9 (16.0-201.6) .15
54.4 (6.5-142.0) 75.0 (37.3-233.9) .31
730 (176-1850) 1900 (370-7000) .02
ular dysfunction; BiVAD, biventricular assist device; CPB, cardiopulmonary bypass;
gery c May 2014
TABLE 3. Post-VAD implantation morbidity
Variable LVAD only (n ¼ 33) LVAD-RVD (n ¼ 10) BiVAD (n ¼ 12)* P value
Postoperative bleedingy 5/33 (15) 2/10 (20) 5/12 (42) .16
Ventilation (d) 5 (1-24) 9.5 (3-22) 6.5 (2-176) .15
RRT 2/33 (6) 4/10 (40) 4/12 (33) .02
VAD, Ventricular assist device; LVAD, left VAD; RVD, right ventricular dysfunction; BiVAD, biventricular assist device; RRT, renal replacement therapy. *Two BiVAD patients
died during implantation and were not included. yRequiring re-exploration or drain insertion.
Karimova et al Perioperative Managementmechanisms have been postulated to play a role in
the development of RVD, including the effects of
cardiopulmonary bypass and acute changes in the RV
loading conditions and geometry.14 Recent studies in adults
have aimed to identify the predictors of RVD preopera-
tively, and variables such as nonischemic etiology of heart
failure, female gender, and elevated bilirubin have been
identified.5,6,15 Compared with adults, our understanding
of RV function after VAD implantation in pediatric
patients is limited; however, preliminary data using
the Interagency Registry for Mechanically Assisted
Circulatory Support adverse events have confirmed the
association of RVD with adverse outcomes in children.16
Preimplantation Status and RVD
Most children will have some degree of RV failure with
organ congestion before VAD implantation. Our results
have suggested that an important association might exist
between preoperative RV impairment and organ congestion
(as evidenced by the greater preoperative central venous
pressure and deranged hepatic and renal function) and
the development of RVD after VAD placement. These
results could be helpful in identifying children at risk of
perioperative RVD who would be likely to need either
medical or mechanical RV support. This also underscores
the importance of the timing of VAD implantation and
optimization of the circulation before VAD implantation
to reduce organ congestion.
Preimplantation Diagnosis and RVD
The preponderance of RVD in patients with a diagnosis
other than DCMwas a notable finding. One could speculateTABLE 4. Nonsurvivor patient characteristics (ordered by year of VAD im
VAD year Age (y) Weight (kg) Diagnosis S
2006 15.8 90 DCM BiVAD
2006 1.3 6.2 DCM BiVAD
2007 4.1 16 DCM LVAD only
2007 11.5 46 DCM LVAD only
2008 0.3 4.3 DCM BiVAD (RV
2009 6.0 15 Non-DCM (restrictive) BiVAD
2010 1.1 8.8 Non-DCM (noncompaction) LVAD only
VAD, Ventricular assist device; DCM, dilated cardiomyopathy; BiVAD, biventricular a
LVAD, left VAD; RVAD, right VAD. *Two patients (both implanted at the beginning of
from ECMO (after 15 and 30 days, respectively) with multiorgan failure and sepsis.
The Journal of Thoracic and Carthat in this heterogeneous group of diagnoses, the reasons
for worse RV function could have been related to factors
such as higher pulmonary vascular resistance in patients
with restrictive physiology or primary right ventricular
myocardial disease, such as in myocarditis. Perhaps more
clinically relevant was the finding that most patients with
DCM were able to be supported with an LVAD only and
that unless exceptional peri-implantation complications
occurred, LVAD is a suitable support choice.1
Role of Echocardiography
We found a limited role for preoperative echocardiogra-
phy in the prediction of postimplantation RVD. The only
preoperative echocardiographic variable associated with
RVD was the qualitative assessment of RV function, a
parameter known to be operator dependent and therefore
of limited reproducibility. A similar result was previously
reported analyzing the preoperative echocardiographic
data from adult VAD recipients.12 Any comparison with
adult data should be done with caution, because adult
studies have included patients with continuous flow pumps
and the etiology of heart failure is different from that of
children. The limited value of preoperative echocardiogra-
phy in predicting RVD in children in the present study
was disappointing; however, more advanced echocardio-
graphic techniques might be more helpful and require
additional investigation.17,18
RVD on LVAD
Our definition of RVD was chosen to describe the
spectrum of RVD in pediatric LVAD recipients and to
distinguish between transient, medically manageable RVDplantation)
upport Support duration (d) Cause of death
Died in OR* Sepsis, liver failure, bleeding
(conversion from ECMO)
Died in OR* Sepsis, multiorgan failure
(conversion from ECMO)
14 Stroke
14 Sepsis, multiorgan failure
AD added day 22) 25 Sepsis, stroke
38 Sepsis, multiorgan failure
69 Stroke
ssist device; OR, operating room; ECMO, extracorporeal membrane oxygenation;
the VAD program) died during implantation; both had undergone late conversion
diovascular Surgery c Volume 147, Number 5 1695
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Mand severe, refractory RVD necessitating mechanical
support with an RVAD. Describing the patients receiving
LVAD support who developed RVD is clinically important,
because these will be the marginal patients for whom
surgeons must make the difficult decision between persist-
ing with LVAD at the cost of increased peri-implantation
morbidity or proceeding to BiVAD. RVD can compromise
both the LVAD and end organ function, and these patients
will require longer inotropic support, prolonged ventilation,
and, often, the use of RRT.19 However, with time, the RV
function in these patients improved, their end organ
function normalized, and their survival rate was excellent
and comparable to that of those with an LVAD without
RVD. To this end, our data showing RV recovery and
good survival in the LVAD patients are informative and
will encourage the use of LVAD in children.
Optimization of RV function starts preoperatively with
aggressive diuresis, inotropes, and pulmonary vasodila-
tors.20,21 In the peri-implantation phase, a ‘‘normal,’’ rather
than an excessive, LVAD output will ensure decompression
of the left ventricle and prevent an acute increase in RV
preload. Echocardiography can be used to assess the
ventricular size, aiming to avoid an acute shift of the
interventricular septum from right to left and worsening
of tricuspid insufficiency. Finally, meticulous hemostasis,
a low threshold for inotrope and pulmonary vasodilator
use, and rhythm control are all important elements of RV
support.9,22
RVD Requiring BiVAD
Great variability exists in practice in terms of BiVAD use
among pediatric centers. One of the early reports of the use
of the Berlin Heart EXCOR in children in North America
reported elective use of BiVAD in all patients, with
excellent survival.23 However, most centers are now much
more restrictive in the use of BiVAD support, with BiVAD
reserved only for cases with severe RVD that cannot be
controlled medically.1,3,9,10,24
A systematic approach to decision making between
LVAD and BiVAD for children has been recently reported
using an algorithm using the peri-implantation clinical
and echocardiographic data.10 This algorithm recognizes
an intermediate category ‘‘between LVAD and BiVAD,’’
giving the surgeon some flexibility to choose the type of
support according to the intraoperative RV performance.
Using this approach, the observed BiVAD rate was 35%,
slightly greater than that in our study.1,10
Risk Factors for BiVAD
ECMO is often used before VAD to either acutely
stabilize patients in cardiogenic shock or as a bridge to
decision.1 In our study, multivariate analysis identified
ECMO as 1 of the independent risk factors for BiVAD.
A similar finding was reported in another pediatric series.21696 The Journal of Thoracic and Cardiovascular SurThe explanation for this finding is likely multifactorial,
including inadequate decompression of the left heart with
ECMO, resulting in lung injury and elevated pulmonary
vascular resistance, and ECMO-related complications
such as infection affecting end organ function. Currently,
most institutions will aim to avoid prolonged ECMO runs
and will consider transition from ECMO to VAD within 7
to 10 days of support. A larger issue might be that the
need for preimplantation ECMO reflects the overall severity
of both end organ failure and myocardial failure.
In a recently reported multicenter study on VAD use in
North America, BiVAD was used less frequently in the
younger patients.1 This was consistent with our observed
trend for infants <1 year old requiring BiVAD support
less frequently, although this finding could have been
confounded by a surgical bias and should be interpreted
with caution.
Other factors associated with BiVAD use in our study
included a non-DCM diagnosis and pre-existing RV failure,
with a secondary impairment of hepatic and renal function.
Combined together, these factors could be useful in
highlighting high-risk patients who are more likely to
develop severe RVD and need a BiVAD.
BiVAD and Postoperative Morbidity and Mortality
In both adult and pediatric reports in which BiVAD
was used as rescue therapy for failing RV function, the
BiVAD patients have had worse outcomes than those with
an LVAD only.2,4 It is debatable whether the greater
mortality with BiVAD use was because these were sicker
patients with more organ compromise or whether having
2 devices resulted into more complications, irrespective of
the preoperative status. Having 2 pumps, instead of 1,
increases the risk of infection and clot formation requiring
more frequent pump changes. It also increases the
postoperative bleeding, exposing patients waiting to be
transplanted to high volume blood transfusions.2
Our study has shown that BiVAD patients are different to
start with: they were sicker, often required ECMO preoper-
atively, and were more likely to have a diagnosis other than
DCM. This would suggest that the greater mortality of
children requiring BiVAD also reflected our current
indications and highlights the importance of timely
initiation of mechanical support.10,11
Study Limitations
Our results should be interpreted in the context of a
retrospective study design. This affected our data
collection; thus, some of the preoperative data collected
retrospectively were not complete (eg, not all patients had
undergone screening hepatic function tests before VAD
implantation), which might have introduced bias. Second,
the choice between LVAD and BiVAD was, in all but 1
case, determined by intraoperative RV performance, andgery c May 2014
Karimova et al Perioperative Managementwe could not exclude a degree of selection bias in borderline
patients with RVD.
CONCLUSIONS
The present study has demonstrated that RVD occurs in
approximately 40% of pediatric VAD recipients and affects
their postoperative morbidity and bridging outcomes.
Children with RVD that was medically managed on
LVAD had a complicated had a complicated postimplanta-
tion course; however, their overall survival was excellent.
Severe RVD requiring BiVAD occurred in 25% patients,
and those children had significantly reduced survival. Pa-
tients with non-DCM and those with impaired RV function
and organ congestion preoperatively were more likely to
develop RVD after VAD implantation. Preoperative
ECMO and an elevated urea level were independent risk
factors for BiVAD.
Additional research into the mechanisms and predictors
of RVD after VAD implantation in children is needed and
will help to optimize their perioperative management and
the decision making between LVAD and BiVAD.
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TABLE E1. Echocardiographic characteristics of patients with LVAD with and without RVD and BiVAD
Echocardiographic
variables LVAD only LVAD-RVD BIVAD P value
Right atrial area (Z-score) 0.54 (3.27 to 7.86) 1.55 (5.52 to 7.82) 1.2 (0.95 to 22.37) .38
Left atrial area (Z-score) 3.55 (1.17 to 15.62) 9.72 (0.05 to 18.55) 2.30 (1.86 to 13.02) .46
TR grade 1 (0 to 3) 2 (0 to 4) 1.5 (0 to 4) .32
TR Vmax (m/s) 2.8 (2.2 to 4.0) 2.7 (1.9 to 4.4) 2.81 (1.8 to 3.0) .79
TV annulus (Z-score) 1.24 (3.98 to 26) 0.12 (3.05 to 12.29) 2.45 (2.59 to 9.77) .71
RV function 0 (0 to 2) 0.5 (0 to 3) 2 (0 to 3) .01
RVEDD (Z-score) 1.67 (5.8 to 6.02) 2.54 (1.48 to 12.35) 3.01 (1.1 to 7.82) .12
LVEDD (Z-score) 5.96 (0.18 to 12.82) 5.88 (4.48 to 11.37) 5.90 (3.76 to 12.65) .81
Data presented as median (range). Significance testing among the 3 groups was performed using the Kruskal-Wallis test. Ventricular function was qualitatively graded as follows:
0, normal; 1, mild; 2, moderate; and 3, severe. LVAD, Left ventricular assist device; RVD, right ventricular dysfunction; BiVAD, biventricular assist device; TR, tricuspid
regurgitation (graded as follows: 0, none; 1, trivial; 2, mild; 3, moderate; and 4, severe); Vmax, maximal velocity; TV, tricuspid valve; RV, right ventricular; LV, left ventricular;
EDD, end-diastolic dimension.
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